Company Logo
The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity clinics, leveraging GLP-1 therapies beyond diabetes, and addressing production cost challenges due to tariffs.
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market · GlobeNewswire Inc.
Dublin, May 21, 2026 (GLOBE NEWSWIRE) — The “Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market is on a robust growth trajectory, expected to expand from $15.5 billion in 2025 to $18.02 billion in 2026, at a CAGR of 16.3%. This growth is driven by rising obesity rates, diabetes drug innovations, and increased healthcare awareness. By 2030, the market is forecasted to reach $32.87 billion, propelled by the approval of new GLP-1 drugs, expansion of obesity clinics, and enhanced insurance coverage. Key trends include increased demand for pharmacological weight management, heightened adoption of GLP-1 therapies beyond diabetes, and improved patient adherence to long-term treatments.
The increasing obesity prevalence is a significant factor driving market growth. In England, 64.5% of adults were reported to be overweight or obese between 2023-2024, highlighting the urgent need for effective treatment options. GLP-1 agonist weight loss drugs are gaining traction due to their proven efficacy in supporting weight loss and metabolic health improvement.
Leading companies are innovating to enhance treatment efficacy and patient outcomes. Notably, Eli Lilly and Company received FDA approval in November 2023 for Zepbound, a chronic weight management medication for adults with obesity-related health conditions. Meanwhile, in December 2023, F. Hoffmann-La Roche AG acquired Carmot Therapeutics for $2.7 billion, gaining access to Carmot’s therapies for obesity and diabetes, including GLP-1 receptor agonists.
The market features major players like Novo Nordisk A/S, Eli Lilly and Company, and Pfizer Inc., among others. North America emerged as the largest region in the market in 2025. The research spans regions including Asia-Pacific, Western Europe, and North America, covering countries such as the USA, UK, China, and Germany.
Tariffs pose challenges by increasing costs of imported active pharmaceutical ingredients and injectable drug devices, impacting hospitals and retail pharmacies. However, they also encourage domestic pharmaceutical production, promoting local GLP-1 formulation.
The GLP-1 agonists weight loss drugs market comprises sales of products like dulaglutide, exenatide, and lixisenatide. These drugs, delivered via parenteral or oral routes, are distributed through hospital and retail pharmacies. Market values represent revenues from the sale of goods and services, as well as related services provided by manufacturers.
The market report offers comprehensive insights, including market size, regional shares, competitor analysis, detailed segments, and opportunities within the GLP-1 agonists weight loss drugs industry. The analysis provides a thorough understanding of the current and future industry outlook.
Key Attributes:
Report Attribute
Details
No. of Pages
250
Forecast Period
2026 – 2030
Estimated Market Value (USD) in 2026
$18.02 Billion
Forecasted Market Value (USD) by 2030
$32.87 Billion
Compound Annual Growth Rate
16.2%
Regions Covered
Global
Report Scope
Markets Covered:
Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
Route of Administration: Parenteral; Oral
Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
Subsegments:
Semaglutide: Ozempic; Wegovy; Rybelsus
Liraglutide: Saxenda; Victoza
Tirzepatide: Mounjaro; Zepbound
Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
Companies Featured
Novo Nordisk A/S
Eli Lilly and Company
Pfizer Inc.
Merck & Co Inc
Boehringer Ingelheim
Hanmi Pharmaceutical
Jiangsu Hengrui Medicine Co Ltd
Zealand Pharma A/S
I-Mab Biopharma Shanghai Co Ltd
Altimmune Inc
BioAge Labs
Innovent Biologics Inc
Viking Therapeutics Inc
Structure Therapeutics Inc
Regor Therapeutics Inc
TheracosBio LLC
Oramed Pharmaceuticals
Amgen Inc
Roche Holding AG
Teva Pharmaceutical Industries Ltd
For more information about this report visit https://www.researchandmarkets.com/r/cpvss
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900